Speech-Language Pathologists in North Syracuse, NY Accepting Medicare

11 Speech-Language Pathologists found. Showing 1 - 11

Lynne Henry Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5590 Bear Rd, North Syracuse, NY 13212 Phone: 315-218-2400

Mrs. Noelle Marie Raymond, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 512 Melrose Dr, North Syracuse, NY 13212 Phone: 315-729-4071

Mrs. Lisa O. Mcvey, LICENSE Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5355 W Taft Rd, North Syracuse, NY 13212 Phone: 315-247-3376

Mr. Daniel David Parsnow, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 320 Gateway Park Dr, North Syracuse, NY 13212 Phone: 315-452-0392

Mrs. Lee Ann Scharbach Mckinney, MS ED. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 205 S Main St, North Syracuse, NY 13212 Phone: 315-218-2200

Ms. Elizabeth Lynne Mcdonald Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 Single Dr, North Syracuse, NY 13212 Phone: 315-458-9477

Mrs. Korie L Allen Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5590 Bear Rd, North Syracuse, NY 13212 Phone: 315-218-2400

Ms. Carol R Guido Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5959 Smith Rd, North Syracuse, NY 13212 Phone: 315-218-2800

Mrs. Elizabeth Anne Jenkins Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5355 W Taft Rd, North Syracuse, NY 13212 Phone: 315-289-7744

Jaclyn Suzanne Storto, MS SPEC ED CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 102 Cynthia Dr, North Syracuse, NY 13212 Phone: 315-559-3689

Mrs. Tracey L Fleming Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5355 W Taft Rd, North Syracuse, NY 13212 Phone: 315-218-3000

News Archive

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

UC Davis cancer researchers have discovered significant differences in radiation-therapy response among patients with oropharyngeal cancer depending on whether they carry the human papillomavirus (HPV), a common sexually transmitted virus. The findings, published online today in The Laryngoscope Journal, could lead to more individualized radiation treatment regimens, which for many patients with HPV could be shorter and potentially less toxic.

Studies show prognostic value for circulating tumor cells in advanced prostate and breast cancer

Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced today that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.

Read more Medical News

› Verified 6 days ago